Nutrition and Its Impact on Quality of Life in Patients with Brain Tumors: A Scoping Review
Simple Summary
Abstract
1. Introduction/Background
2. Methods
3. Results
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Data Availability Statement
Acknowledgments
Conflicts of Interest
Abbreviations
| QoL | Quality of Life |
| KD | Ketogenic diet(s) |
| CNS | Central nervous system |
| AYA | Adolescents and young adults |
| PRISMA | Preferred Reporting Items for Systematic Review and Meta-analyses |
| ASPEN | American Society for Parenteral and Enteral Nutrition |
| ESPEN | European Society for Clinical Nutrition and Metabolism |
| GBM | Glioblastoma multiforme |
| PET | Positron Emission Tomography |
| EORTC | European Organization for Research and Treatment of Cancer |
| BDI | Beck Depression Inventory |
| BFI | Brief Fatigue Inventory |
| ESAS | Edmonton Symptom Assessment System |
| MCT | Medium Chain Triglycerides |
References
- Neff, C.; Price, M.; Cioffi, G.; Kruchko, C.; Waite, K.A.; Barnholtz-Sloan, J.S.; Ostrom, Q.T. Complete prevalence of primary malignant and nonmalignant brain tumors in comparison to other cancers in the United States. Cancer 2023, 129, 2514–2521. [Google Scholar] [CrossRef] [Scilit]
- Arends, J. Malnutrition in cancer patients: Causes, consequences and treatment options. Eur. J. Surg. Oncol. 2024, 50, 107074. [Google Scholar] [CrossRef] [Scilit]
- McCall, M.; Leone, A.; Cusimano, M. Nutritional Status and Body Composition of Adult Patients with Brain Tumours Awaiting Surgical Resection. Can. J. Diet. Pract. Res. 2014, 75, 148–151. [Google Scholar] [CrossRef] [Scilit]
- Taphoorn, M.J.; Sizoo, E.M.; Bottomley, A. Review on quality of life issues in patients with primary brain tumors. Oncologist 2010, 15, 618–626. [Google Scholar] [CrossRef] [Scilit]
- Martin-McGill, K.J.; Marson, A.G.; Tudur Smith, C.; Young, B.; Mills, S.J.; Cherry, M.G.; Jenkinson, M.D. Ketogenic diets as an adjuvant therapy for glioblastoma (KEATING): A randomized, mixed methods, feasibility study. J. Neurooncol. 2020, 147, 213–227. [Google Scholar] [CrossRef] [Scilit]
- Rieger, J.; Bähr, O.; Maurer, G.D.; Hattingen, E.; Franz, K.; Brucker, D.; Walenta, S.; Kämmerer, U.; Coy, J.F.; Weller, M.; et al. ERGO: A pilot study of ketogenic diet in recurrent glioblastoma. Int. J. Oncol. 2014, 44, 1843–1852. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Maeyama, M.; Tanaka, K.; Nishihara, M.; Irino, Y.; Shinohara, M.; Nagashima, H.; Tanaka, H.; Nakamizo, S.; Hashiguchi, M.; Fujita, Y.; et al. Metabolic changes and anti-tumor effects of a ketogenic diet combined with anti-angiogenic therapy in a glioblastoma mouse model. Sci. Rep. 2021, 11, 79. [Google Scholar] [CrossRef] [Scilit]
- Amaral, L.J.; Gresham, G.; Kim, S.; Tighiouart, M.; Nelson, T.A.; Welborn, A.; Lockshon, L.; Noorvash, B.; Rudnick, J.D.; Irwin, S.A.; et al. A phase 1 safety and feasibility trial of a ketogenic diet plus standard of care for patients with recently diagnosed glioblastoma. Sci. Rep. 2025, 15, 21064. [Google Scholar] [CrossRef] [Scilit]
- Duraj, T.; Kalamian, M.; Zuccoli, G.; Maroon, J.C.; D’Agostino, D.P.; Scheck, A.C.; Poff, A.; Winter, S.F.; Hu, J.; Klement, R.J.; et al. Clinical research framework proposal for ketogenic metabolic therapy in glioblastoma. BMC Med. 2024, 22, 578. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Voss, M.; Wagner, M.; von Mettenheim, N.; Harter, P.N.; Wenger, K.J.; Franz, K.; Bojunga, J.; Vetter, M.; Gerlach, R.; Glatzel, M.; et al. ERGO2: A Prospective, Randomized Trial of Calorie-Restricted Ketogenic Diet and Fasting in Addition to Reirradiation for Malignant Glioma. Int. J. Radiat. Oncol. Biol. Phys. 2020, 108, 987–995. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Voss, M.; Wenger, K.J.; von Mettenheim, N.; Bojunga, J.; Vetter, M.; Diehl, B.; Franz, K.; Gerlach, R.; Ronellenfitsch, M.W.; Harter, P.N.; et al. Short-term fasting in glioma patients: Analysis of diet diaries and metabolic parameters of the ERGO2 trial. Eur. J. Nutr. 2022, 61, 477–487. [Google Scholar] [CrossRef] [Scilit]
- Bakish, J.; Hargrave, D.; Tariq, N.; Laperriere, N.; Rutka, J.T.; Bouffet, E. Evaluation of dietetic intervention in children with medulloblastoma or supratentorial primitive neuroectodermal tumors. Cancer 2003, 98, 1014–1020. [Google Scholar] [CrossRef] [Scilit]
- van der Louw, E.J.T.M.; Olieman, J.F.; van den Bemt, P.M.L.A.; Bromberg, J.E.C.; Oomen-de Hoop, E.; Neuteboom, R.F.; Catsman-Berrevoets, C.E.; Vincent, A.J.P.E. Ketogenic diet treatment as adjuvant to standard treatment of glioblastoma multiforme: A feasibility and safety study. Ther. Adv. Med. Oncol. 2019, 11, 1758835919853958. [Google Scholar] [CrossRef] [Scilit]
- Klein, P.; Tyrlikova, I.; Zuccoli, G.; Tyrlik, A.; Maroon, J.C. Treatment of glioblastoma multiforme with “classic” 4:1 ketogenic diet total meal replacement. Cancer Metab. 2020, 8, 24. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Nebeling, L.C.; Miraldi, F.; Shurin, S.B.; Lerner, E. Effects of a ketogenic diet on tumor metabolism and nutritional status in pediatric oncology patients: Two case reports. J. Am. Coll. Nutr. 1995, 14, 202–208. [Google Scholar] [CrossRef] [Scilit]
- Panhans, C.M.; Gresham, G.; Amaral, L.J.; Hu, J. Exploring the Feasibility and Effects of a Ketogenic Diet in Patients with CNS Malignancies: A Retrospective Case Series. Front. Neurosci. 2020, 14, 390. [Google Scholar] [CrossRef] [Scilit]
- Perez, A.; van der Louw, E.; Nathan, J.; El-Ayadi, M.; Golay, H.; Korff, C.; Ansari, M.; Catsman-Berrevoets, C.; von Bueren, A.O. Ketogenic diet treatment in diffuse intrinsic pontine glioma in children: Retrospective analysis of feasibility, safety, and survival data. Cancer Rep. 2021, 4, e1383. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Cho, K.H.; Han, E.Y.; Jung, M.K.; Kang, C.M.; Shin, J.C.; Im, S.H. Effects of protein-enriched nutritional support on skeletal muscle mass and rehabilitative outcomes in brain tumor patients: A randomized controlled trial. Sci. Rep. 2024, 14, 12909. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- World Health Organization. Cancer Prevention. World Health Organization. Available online: www.who.int/health-topics/cancer#tab=tab_2 (accessed on 10 January 2026).
- Zhang, F.F.; Cudhea, F.; Shan, Z.; Michaud, D.S.; Imamura, F.; Eom, H.; Ruan, M.; Rehm, C.D.; Liu, J.; Du, M.; et al. Preventable Cancer Burden Associated with Poor Diet in the United States. JNCI Cancer Spectr. 2019, 3, pkz034. [Google Scholar] [CrossRef] [Scilit]
- Sergentanis, T.N.; Tsivgoulis, G.; Perlepe, C.; Ntanasis-Stathopoulos, I.; Tzanninis, I.G.; Sergentanis, I.N.; Psaltopoulou, T. Obesity and Risk for Brain/CNS Tumors, Gliomas and Meningiomas: A Meta-Analysis. PLoS ONE 2015, 10, e0136974. [Google Scholar] [CrossRef] [Scilit]
- Schmidt, M.; Pfetzer, N.; Schwab, M.; Strauss, I.; Kämmerer, U. Effects of a ketogenic diet on the quality of life in 16 patients with advanced cancer: A pilot trial. Nutr. Metab. 2011, 8, 54. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Khodabakhshi, A.; Seyfried, T.N.; Kalamian, M.; Beheshti, M.; Davoodi, S.H. Does a ketogenic diet have beneficial effects on quality of life, physical activity or biomarkers in patients with breast cancer: A randomized controlled clinical trial. Nutr. J. 2020, 19, 87. [Google Scholar] [CrossRef] [Scilit]
- Trujillo, E.B.; Kadakia, K.C.; Thomson, C.; Zhang, F.F.; Livinski, A.; Pollard, K.; Mattox, T.; Tucker, A.; Williams, V.; Walsh, D.; et al. Malnutrition risk screening in adult oncology outpatients: An ASPEN systemic review and clinical recommendations. J. Parenter. Enter. Nutr. 2024, 48, 874–894. [Google Scholar] [CrossRef] [Scilit]
- Muscaritoli, M.; Arends, J.; Bachmann, P.; Baracos, V.; Barthelemy, N.; Bertz, H.; Bozzetti, F.; Hütterer, E.; Isenring, E.; Kaasa, S.; et al. ESPEN practical guideline: Clinical Nutrition in Cancer. Clin. Nutr. 2021, 40, 2898–2913. [Google Scholar] [CrossRef] [Scilit]
- Gowin, K.; Muminovic, M.; Zick, S.M.; Lee, R.T.; Lacchetti, C.; Mehta, A. Integrative Therapies in Cancer Care: An Update on the Guidelines. Am. Soc. Clin. Oncol. Educ. Book 2024, 44, e431554. [Google Scholar] [CrossRef] [Scilit]
- Forbes, C.C.; Swan, F.; Greenley, S.L.; Lind, M.; Johnson, M.J. Physical activity and nutrition interventions for older adults with cancer: A systematic review. J. Cancer Surviv. 2020, 14, 689–711. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Cheng, X.; Yang, Z. Effect of resistance training on inflammatory markers in middle-aged and older adults: A meta-analysis. Arch. Gerontol. Geriatr. 2024, 126, 105536. [Google Scholar] [CrossRef] [Scilit] [PubMed]

| Article Citation | Type of Study | Patient Population | # Started Intervention | # Completed the Intervention | Intervention | Primary Objective | Duration of Study | Assessment Tools Used | QOL Results |
|---|---|---|---|---|---|---|---|---|---|
| Bakish J et al. 2003 [12] | Retrospective case series | Children with newly diagnosed medulloblastoma and supratentorial primitive neuroectodermal tumor | 103 | 103 | Oral diet counseling vs. enteral nutrition vs. parenteral nutrition | Percent change in body weight | Over 10 years | Descriptive | Enteral nutrition facilitates weight gain and therefore improves the quality of life for the patient and the caregiver |
| Rieger J et al. 2014 [6] | Clinical trial | Adults with recurrent GBM | 20 | 17 | KD with no caloric restriction | Feasibility | 3–13 weeks (until disease progression) | Descriptive | 3 patients discontinued due to the diet negatively affecting QOL |
| Van der Louw et al. 2019 [13] | Clinical trial | Adult patients with GBM | 9 | 6 | KD (4:1 ratio) | Feasibility | 14 weeks | EORTC QLQ-C-30 questionnaire | No significant change over the course of the study |
| Klein P et al. 2020 [14] | Clinical trial | Adult patients with either newly diagnosed GBM treatment or recurrent GBM | 8 | 5 | KD (4:1 ratio) | Feasibility, safety, and tolerability | 6 months | Descriptive | Case description reporting “excellent quality of life” |
| Martin-McGill KJ et al. 2020 [5] | Clinical trial with embedded qualitative study | Adult patients with recently diagnosed GBM | 10 | 4 completed 3 months, 3 completed 12 months | Modified KD or medium-chain triglyceride KD | Retention rate at three months | 3 months (primary end point) with an option to continue for a total of 12 months (secondary end point) | EORTC QLQ C30 and BN20 questionnaires | Patients who maintained KD had a Global Health Status above the brain cancer reference value, while patients who withdrew fell below the reference value |
| Nebeling LC et al. 2020 [15] | Case reports | Pediatric patients with advanced stage malignant astrocytoma tumors | 2 | 2 | MCT oil-based KD | Tumor glucose metabolism assessed by PET uptake at the tumor site | 8 weeks | Descriptive | One patient with “marked progress in skill development (gait, mobility, speech, hand coordination) and mood” “QOL greatly improved” |
| Panhans CM et al. 2020 [16] | Retrospective case series | Adult patients with GBM, astrocytoma, or oligodendroglioma | 12 | 8 | KD (3:1 ratio) | Feasibility and safety | 120 days | ESAS assessment, descriptive | Reported improvement in fatigue in 8/12 patients and in mood in 7/12 patients. Patient case descriptions of improved QOL |
| Voss M, Wagner M et al. 2020, 2022 [10,11] | Clinical trial | Adult patients with recurrent malignant gliomas (GBM, gliosarcoma, or malignant progression of lower grade glioma) | 23 | 20 | Calorically restricted KD and intermittent fasting | Progression-free survival | 9 days | EORTC QLQ C30 and BN20 questionnaires | No significant difference between the two groups during treatment or at later follow-up |
| Perez, A. et al. 2021 [17] | Retrospective case series | Children with diffuse intrinsic pontine glioma | 6 | 5 | KD (varied) | Feasibility, safety, and overall survival | 3 months | Descriptive | “Some cases with improvements of some symptoms resulting in a better participation in daily life activities” |
| Cho KH et al. 2024 [18] | Clinical trial | Adult with different types of brain tumors | 30 | 20 | Protein supplements | Muscle strengthening and functional gain | 6 weeks | Beck Depression Inventory (BDI) and Brief Fatigue Inventory (BFI) | No statistical significance in BDI and BFI before and after assessment. Improved pinch grasp and 6 min walk in the protein supplementation group |
| Amaral LJ et al. 2025 [8] | Clinical trial | Adult patients with recently diagnosed GBM | 20 | 17 | KD (3:1 ratio) | Safety | 16 weeks | EORTC QLQ-C30 and QLQ BN-20 questionnaires | No statistically significant changes over the study. Non-significant results: Appetite ↓ Constipation ↑ N/v ↑ Overall QoL ↑ Seizure severity ↓ Headaches ↓ |
| Trials Number | Trial Name | Trial Status | Intervention | Primary Objective | Site(s) | QoL Measurement | Timing of QoL Assessment |
|---|---|---|---|---|---|---|---|
| NCT05428852 | Keto-Brain: Investigating the Use of Ketogenic Diets in Brain Metastases | Recruiting | Ketogenic diet | Feasibility | Columbus, Ohio, United States, 43210 | Hearth Hope Index (HHI), SF-36, cancer-specific FACT surveys, Brief Pain Inventory, Brief Fatigue Inventory, and self-report diaries | Baseline up to 16 weeks |
| NCT05564949 | A Ketogenic Diet as a Complementary Treatment for Patients with High-grade Gliomas and Brain Metastases | Recruiting | Ketogenic diet | Overall survival | Athens, Greece, 12462. Chaïdári, Athens, Greece, 12461 | Functional Assessment of Cancer Therapy—Brain (FACT-Br) | Baseline, 3 months, 6 months, 12 months |
| NCT06309251 | Effectiveness and Impact on the Quality of Life of the Ketogenic Diet in Pediatric Patients | Recruiting | Ketogenic diet | Nutritional adequacy | Milan, MI, Italy, 20154. Pavia, PV, Italy, 27100. Roma, RM, Italy, 00165 | Non-validated questionnaire administered to parents with qualitative open and closed questions | 6 months (12 months optional) |
| NCT06949891 | KETOgenic Diet Therapy in Patients with ACROmegaly | Recruiting | Ketogenic diet | Difference in IGF-1 | Rotterdam, Netherlands, 3015 GE | Acromegaly Quality of Life questionnaire. Patient-Assessed Acromegaly Symptom Questionnaire. D-KETOcheck questionnaire | At baseline, 3 months, and 6 months. |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.
Share and Cite
Banihani, J.; Cramer, S.; Hu, J. Nutrition and Its Impact on Quality of Life in Patients with Brain Tumors: A Scoping Review. Cancers 2026, 18, 392. https://doi.org/10.3390/cancers18030392
Banihani J, Cramer S, Hu J. Nutrition and Its Impact on Quality of Life in Patients with Brain Tumors: A Scoping Review. Cancers. 2026; 18(3):392. https://doi.org/10.3390/cancers18030392
Chicago/Turabian StyleBanihani, Jude, Stephanie Cramer, and Jethro Hu. 2026. "Nutrition and Its Impact on Quality of Life in Patients with Brain Tumors: A Scoping Review" Cancers 18, no. 3: 392. https://doi.org/10.3390/cancers18030392
APA StyleBanihani, J., Cramer, S., & Hu, J. (2026). Nutrition and Its Impact on Quality of Life in Patients with Brain Tumors: A Scoping Review. Cancers, 18(3), 392. https://doi.org/10.3390/cancers18030392

